Skip to main content
Livermore
Livermore
ZHEN

BioLineRx Ltd.

BLRX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001498403

No open-market purchases or sales by BioLineRx Ltd. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $206.7K in total; no superinvestor holds it.

Holders of 5% or more of BLRX

Holders whose latest Schedule 13D or 13G filing reports 5% or more of BioLineRx Ltd., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of BLRX
HolderLatest formStakeChangeFirst filedLatest filingFiling
Highbridge Capital Management LLC13G7.20%173.0M sharesNewAug 14, 20251 filingAug 14, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

9 Schedule 13D and 13G filings on BioLineRx Ltd., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on BLRX
Filed (ET)FilerFormStakeChangeEvent dateFiling
Aug 14, 20254:03 PM ETHighbridge Capital Management LLC13G7.20%173.0M sharesNewJun 30, 2025SEC
Jan 10, 20256:51 PM ETIntracoastal Capital, LLCand 2 others13G4.99%102.2M shares–Below 5%Jan 6, 2025SEC
Oct 26, 2023Hong Seng Technology Ltd13DOld format–New–SEC
Feb 11, 2022Intracoastal Capital, LLC13G/AOld format–––SEC
Feb 16, 2021Altium Capital Management LP13G/AOld format–––SEC
Feb 16, 2021Novartis Pharma AG13G/AOld format–––SEC
Feb 12, 2021Senvest Management, LLC13G/AOld format–––SEC
Jan 29, 2021Intracoastal Capital, LLC13G/AOld format–––SEC
Jan 6, 2021Sabby Management, LLC13G/AOld format–––SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell BioLineRx Ltd. shares.

No Form 144 notices for BioLineRx Ltd. are on file.